Dual effect of IL‐7/IL‐7R signalling on the osteoimmunological system: a potential therapeutic target for rheumatoid arthritis

Immunology ◽  
2021 ◽  
Author(s):  
Haiyan Xu ◽  
Li Cai ◽  
Zijian Li ◽  
Lili Zhang ◽  
Guojue Wang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Dual Effect ◽  
Potential Therapeutic Target ◽  
System A

Analysis of DIP2C as a novel regulator for epithelial-mesenchymal transition of rheumatoid arthritis synovium and a potential therapeutic target

Impact ◽  
2021 ◽  
Vol 2021 (8) ◽  
pp. 28-30
Author(s):  
Masao Tanaka
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Epithelial Mesenchymal Transition ◽  
Poor Response ◽  
Associate Professor ◽  
Therapeutic Interventions ◽  
Response To Treatment ◽  
Potential Therapeutic Target ◽  
Mesenchymal Transition ◽  
Long Time

Rheumatoid arthritis (RA) is an autoimmune disease that can cause damage to the joints, cartilage and bone. There is no cure but early diagnosis can help mitigate damage. Sometimes RA is particularly difficult to treat, for example when the disease took a long time to be diagnosed. Associate Professor Masao Tanaka, Graduate School of Medicine, Kyoto University, Japan, leads a team of researchers working to improve understanding of the causes of poor response to treatment in RA with a long morbidity. The goal is to restore patients' therapeutic responsiveness, thereby improving outcomes. A previous focus for Tanaka was on a protein called FSTL1. He is now exploring DIP2 as a binding molecule for FSTL1. Other important mechanisms Tanaka is exploring are DNA methylation and the mechanisms of carnitine, which has been found to decrease a variety of activation signalling by inhibiting ceramide production in T cells. He and the team are exploring the involvement of these mechanisms in DIP2. In his most recent investigations, Tanaka is exploring DIP2C as a novel regulator for epithelial-mesenchymal transition of RA synovium and a potential therapeutic target. He is focusing on molecules that are expressed in the cells in joints, making the work directly applicable to RA. The team is carrying out a cohort study called KURAMA (Kyoto University Rheumatoid Arthritis Management Alliance) that involves around 2,000 outpatients with RA. Ultimately, Tanaka hopes to identify a reproducible combination of patient conditions and therapeutic interventions that achieve better treatment results for RA patients.

scholarly journals Interleukin 22, a Potential Therapeutic Target for Rheumatoid Arthritis

2012 ◽  
Vol 39 (11) ◽  
pp. 2220-2221 ◽  
Author(s):  
QIANG XIE ◽  
SHI-CUN WANG ◽  
JUN LI
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Interleukin 22

MicroRNA-323-3p: a new biomarker and potential therapeutic target for rheumatoid arthritis

2013 ◽  
Vol 34 (5) ◽  
pp. 721-722 ◽  
Author(s):  
Tao Xu ◽  
Cheng Huang ◽  
Zhaolin Chen ◽  
Jun Li
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

scholarly journals Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?

2012 ◽  
Vol 71 (10) ◽  
pp. 1724.1-1732 ◽  
Author(s):  
Klaus W Frommer ◽  
Andreas Schäffler ◽  
Christa Büchler ◽  
Jürgen Steinmeyer ◽  
Markus Rickert ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

Interleukin-27 as a potential therapeutic target for rheumatoid arthritis: has the time come?

2013 ◽  
Vol 32 (10) ◽  
pp. 1425-1428 ◽  
Author(s):  
Fang Gong ◽  
Yu-Hong Pan ◽  
Xuan Huang ◽  
Jiang Chen ◽  
Jin-Hua Xiao ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Potential Therapeutic Target ◽  
Interleukin 27

IRAK1, a potential therapeutic target for rheumatoid arthritis?

2012 ◽  
Vol 33 (12) ◽  
pp. 3069-3070 ◽  
Author(s):  
Qiang Xie ◽  
Shi-Cun Wang ◽  
Jun Li
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Target ◽  
Potential Therapeutic Target

scholarly journals The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Aron Chakera ◽  
Sophia C. Bennett ◽  
Olivier Morteau ◽  
Paul Bowness ◽  
Raashid A. Luqmani ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
T Cells ◽  
Therapeutic Target ◽  
Patient Characteristics ◽  
Helper T Cells ◽  
Immunoglobulin Superfamily ◽  
Systemic Autoimmune Disease ◽  
Follicular Helper T Cells ◽  
Potential Therapeutic Target ◽  
Follicular Helper

Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting synovial joints in which the development of autoantibodies represents a failure of normal tolerance mechanisms, suggesting a role for follicular helper T cells (TFH) in the genesis of autoimmunity. To determine whether quantitative or qualitative abnormalities in the circulatingTFHcell population exist, we analysed by flow cytometry the number and profile of these cells in 35 patients with RA and 15 matched controls. Results were correlated with patient characteristics, including the presence of autoantibodies, disease activity, and treatment with biologic agents. CirculatingTFHcells from patients with RA show significantly increased expression of the immunoglobulin superfamily receptor CD200, with highest levels seen in seropositive patients (P=0.0045) and patients treated with anti-TNFαagents (P=0.0008). This occurs in the absence of any change inTFHnumbers or overt bias towards Th1, Th2, or Th17 phenotypes. CD200 levels did not correlate with DAS28 scores (P=0.887). Although the number of circulatingTFHcells is not altered in the blood of patients with RA, theTFHcells have a distinct phenotype. These differences associateTFHcells with the pathogenesis of RA and support the relevance of the CD200/CD200R signalling pathway as a potential therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document